Concepedia

Sarah Brand

SB

Statistics

Publications

11

Citations

361

H-Index

11

Active since

2014

Affiliations

Ithaka Harbors(Current)

Boehringer Ingelheim (United States)

Boehringer Ingelheim (Germany)

Boehringer Ingelheim (Brazil)

Heidelberg University

Sarah Brand is an author at Ithaka Harbors specializing in cost-effectiveness analysis, cost-effectiveness modeling, and pharmacotherapy.

ORCID

Publications per year

2014–2023

11

Publications

11

Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK

Virginia Becerra, Alfredo Gracia, Kamal Desai et al. · BMJ Open · 2015 · 89 citations · Full text

, , +17

Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial

Odette S. Reifsnider, Christoph Wanner, Egon Pfarr et al. · American Journal of Kidney Diseases · 2021 · 50 citations · Full text

, , +17

Association between age at disease onset of anti-neutrophil cytoplasmic antibody–associated vasculitis and clinical presentation and short-term outcomes

Sara Monti, Anthea Craven, Catherine Klersy et al. · Lara D. Veeken · 2020 · 39 citations · Full text

, , +14

Cost-Effectiveness of Empagliflozin in the UK in an EMPA-REG OUTCOME Subgroup with Type 2 Diabetes and Heart Failure

Odette S. Reifsnider, Jennifer Franke, Joseph H. Lee et al. · ESC Heart Failure · 2020 · 30 citations · Full text

, , +17

Quality of Life and its Determinants in Patients With Adrenal Insufficiency: A Survey Study at 3 Centers in the United States

Dingfeng Li, Sarah Brand, Oksana Hamidi et al. · The Journal of Clinical Endocrinology & Metabolism · 2022 · 28 citations · Full text

, , +14

1–5 of 11